Disclaimer
NovusValue.com is not a broker or dealer, and none of its content represents recommendations to buy or sell securities. Information provided on the site is not intended as investment advice. Novus Value is not liable for damages from using its content, including investment losses. Past performance does not indicate future results, and information is not guaranteed for accuracy or completeness.1-Line Summary
Bio-Techne Corporation develops and sells life science reagents and diagnostic products worldwide.
Bio-Techne Corporation specializes in developing, manufacturing, and selling life science reagents, instruments, and services for research and diagnostics globally. The company operates through two main segments: Protein Sciences and Diagnostics and Genomics. Its products encompass a wide range of high-quality biological reagents and analytical tools, aiding drug discovery and molecular diagnostics to enhance disease treatment and detection.
The Protein Sciences segment leads in providing biological reagents used in life science research and diagnostics, while the Diagnostics and Genomics segment focuses on developing diagnostic assays and reagents for the healthcare market. Bio-Techne's strategy emphasizes growth via innovation and acquisitions, targeting high-growth areas such as cell and gene therapy and liquid biopsies, along with expanding its global reach and enhancing customer experiences.
Automaticly searches the internet using AI for the current investing thesis for Bio-Techne Corporation (TECH) and summarizes it. Only available for paid users.